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https://doi.org/10.1186/s12885-019-5863-2RESEARCH ARTICLE Open AccessLong term outcome after 48 Gy stereotactic
ablative body radiotherapy for peripheral
stage I non-small cell lung cancer
Emilie Dubaere1, Mathilde Goffaux2, Marie Wanet1, Benoit Bihin2,3, Céline Gheldof1, Anne-Sophie Demoulin4,
Antoine Bolly1, Frederique Bustin4, Fabrice Duplaquet3, Paul-Emile Baugnee5, Michel Gustin4, Vincent Hers5,
Fabienne Maisin1, Eric Marchand2,3, Sebahat Ocak3,8, Lionel Pirard3, Oswald Vancutsem6, Evelyne Van Neck7,
Guy Vandermoten5, Luminata Zaharia5 and Vincent Remouchamps1,2*Abstract
Background: To evaluate the outcome of patients treated with stereotactic ablative body radiotherapy (SABR) with
curative intent for stage I non-small cell lung cancer (NSCLC) with regard to local, regional and distant tumor
control, disease-free survival (DFS), overall survival (OS) and toxicity.
Methods: Data of 300 patients treated with SABR for NSCLC cancer for the period of November 2007 to June 2016
were retrospectively analyzed. Of which, 189 patients had single primary lung lesion and were included in the
study. The prescribed dose for the tumor was 48 Gy, given in 12 Gy × 4 fractions for all patients. In 2010, an
improved protocol was established in advanced technology for the planning CT, dose calculation and imaging.
Cumulative incidence function (CIF) of local, regional, distant or any recurrences were computed using competing
risk analysis with death as a competing event. Survivals (DFS and OS) were estimated using the Kaplan-Meier
method and Cox proportional regression was used for comparisons. Toxicities were graded according to the
common terminology criteria for adverse events version 4.0 (CTCAE v.4).
Results: Diagnosis was histologically confirmed in 42% of the patients (N = 80). At 1, 2 and 4 years, the cumulative
incidence function (CIF) of local relapses were 8% [4–13%], 15% [10–21%] and 18% [12–25%], the CIF of regional
relapses were 4% [2–8%], 10% [6–16%] and 12% [8–19%], the CIF of distant relapses were 9% [5–14%], 15% [11–22%]
and 20% [15–28%] and the CIF of any relapses were 14% [10–20%], 28% [22–36%], 34% [27–43%], respectively. After 1,
2 and 4 years, the OS rates were 83% [95% CI: 78–89%] (N = 128), 65% [95% CI: 57–73%] (N = 78) and 37% [95% CI:
29–47%] (N = 53), respectively. The median survival time was 37months. The DFS after 1, 2 and 4 years reached 75%
[95% CI: 68–81%] (N = 114), 49% [95% CI: 42–58%] (N = 60) and 31% [95% CI: 24–41%] (N = 41), respectively. No grade
4 or 5 toxicity was observed.
Conclusions: We observed a long-term local control and survival after SABR for peripheral stage I NSCLC in this large
series of patients with the expected low toxicity.
Keywords: Stereotactic ablative radiotherapy, Lung cancer, Non-small cell lung cancer, Survival© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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Partially presented as posters at the 2010, 2012, 2014 and 2018 meetings of
the European Society of Therapeutic Radiation Oncology (ESTRO).
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The standard treatment for stage I non-small cell lung
cancer (NSCLC) is surgery, with excellent local control
and survival outcome [1, 2]. However, a substantial
proportion of patients are unfit to tolerate any type of
surgical resection due to their comorbidities. Further-
more, a small proportion of patients rejected the option
of surgery based on personal reasons. The alternative
treatment for these patients was no treatment at all or
primary conventional radiotherapy with a total dose of
60 to 70 Gy in fractions of 2 Gy a day [3]. The outcome
after conventional radiotherapy has been relatively poor,
with a long term survival of 15–30% and local control
only being 40–50% [4, 5]. Due to advances in radiation
modalities, the management upgraded to stereotactic ab-
lative body radiotherapy (SABR). Better local control
may be reached by increasing radiation therapy dose,
resulting in better overall survival (OS) [6]. SABR is a ra-
diation technique which assigns a high radiation dose
with precise delivery and high conformity while avoiding
radiosensitive organs surrounding the tumor. In com-
parison to conventional radiotherapy, which is delivered
over several weeks, SABR is typically administered in
few fractions, typically 3 to 10 fractions, reducing the
overall treatment time. In addition, the toxicity profile of
this non-invasive treatment is quite favorable [7, 8]. An
excellent clinical outcome with SABR has been observed
with several studies showing comparable results to those
obtained through surgery. Local control rates are ap-
proximately 80 to 90% when schedules with biologically
effective dose (BED) larger than 100 Gy are used [9–12].
We retrospectively evaluated the local, regional and
distant tumor control, as well as the disease-free survival
(DFS), OS and toxicity in our unselected patient popula-
tion that was treated over the last 10 years. In recent
years, there have been advances in the radiotherapy
techniques, delivery for SABR and treatment methods in
our department, however, the 12 Gy × 4 fractions pre-
scription has remained unaltered.
Methods
Patient population
Data of 300 patients with stage I NSCLC (American
Joint Committee on Cancer, seventh edition T1a T1b-
T2 N0M0) [13] treated for peripheral lung lesions with
a standard SABR protocol between November 2007 and
June 2016 were retrospectively reviewed. The review was
approved by the Institutional Review Board under the
current legislation (Ethics Committee from CHU UCL
Namur, site Ste. Elisabeth and its President, Dr. Isabelle
Mathieu). The acceptance date of the ethics committee
was 21 October 2016. Patients with central lesions, mul-
tiple nodules, metastatic lung lesions or synchronous
cancers were excluded. Also, patients were recruitedfrom several institutions but treated in a single radiation
therapy department. In-hospital medical files and letters
from the referring pneumologist or oncologist for
patients followed-up on in collaborating institutions
were reviewed.
An experienced multidisciplinary team carefully
studied patient’s characteristics (i.e. smoking history and
age) and their images before suggesting treatment with-
out histological confirmation. There was a need for an
adequate record of the growth of the tumor size over
time, a high 18F-FDG-PET uptake and morphological
abnormalities suggestive of malignancy [14, 15].
When follow-up is lost, which usually happens after
supportive care, the vital status was obtained after phone
calls to the family or general practitioners.
Procedures
Image acquisition
All patients underwent fluoro-deoxy-glucose positron
emission tomography and computed tomography (FDG-
PET-CT) for staging, usually contrast-enhanced. All pa-
tients underwent planning CT with a slice thickness of
2.5 mm and a four-dimensional (4D)-CT on a dedicated
CT simulator (General Electric RT16, General Electric
Company, Boston). Two different 4D image acquisition
procedures were used according to the date of patient
inclusion in the study. Initially, a 3 phase CT including a
physiological inspiration, expiration and free breathing
were performed. From the end of 2009, a 10 phase 4D-
CT using the Real-time Position Management (RPM®,
Varian Medical Systems, Palo Alto, CA, USA) device
was used. Patients were immobilized with a thermoplas-
tic mask. In 2010, the diaphragmatic compression was
added. Images were transferred to the Eclipse planning
system (TPS; Eclipse version 8 to 11 during this period,
Varian Medical Systems, Palo Alto, CA, USA).
Organs at risk and volumes delineation
The gross tumor volume (GTV) included the visible
tumor, delineated with a lung windowing setting (level −
600 Hounsfield Unit (HU); width 1600 HU). An internal
target volume (ITV) encompassing all tumor position in
the breathing cycle was delineated using all phases of
the 4D-CT. No clinical target volume (CTV) margins
were used. An isotropic margin of 5 mm around the ITV
was used to create the setup margin component of plan-
ning target volume (PTV).
The organs at risk (OARs), that is, the spinal cord,
lungs, heart, great vessels, proximal bronchi, brachial
plexus, chest wall, trachea, esophagus and skin, were
delineated depending on the location of the tumor.
According to reports 62 and 83 of the International
Commission on Radiation Units and measurements, a
safe 5 mm margin was added to the spinal cord as
Dubaere et al. BMC Cancer          (2019) 19:639 Page 3 of 8planning at risk volume (PRV). Adding a PRV for the
esophagus or 4D delineation according to the location of
the target was hardly necessary as they were all periph-
eral lesions.
Treatment planning
For all patients, the total prescribed dose to the PTV
was 48 Gy in 12 Gy × 4 fractions. Treatments were ad-
ministered on a linear accelerator (Clinac® 21EX; Varian
Medical Systems, Palo Alto, CA, USA and Novalis TX;
Varian Medical Systems, Palo Alto, CA, USA) delivering
6 MV photons. Dose constraints for OARs and target
volumes (TVs) were compliant with the national proto-
col derived from RTOG trial 0915. From 2007 to 2010,
most patients were treated with multiple (minimum of
seven) coplanar and/or non-coplanar beams with three-
dimensional conventional radiotherapy (3D-CRT) using
pencil beam dose calculation algorithm (Type I dose
computation algorithm). Twenty five percent of patients
from the period before 2010 with limited breathing mo-
tion (less than 5 mm) on inspiration and expiration CT
were treated on the Tomotherapy unit, while the others
were treated on a 5 mm leaves Millenium multi-leaf
collimator (MLC) linear accelerator. The total dose was
prescribed at the isocenter, accepting 80–95% around
the PTV [16]. Fractions were delivered every other day.
On the Tomotherapy system, a type II calculation algo-
rithm was used. From 2010, all patients were treated
with volumetric modulated arc therapy (VMAT) with
the Varian method named Rapidarc on a Novalis Tx lin-
ear accelerator using an analytic anisotropic algorithm
(AAA) calculation for treatment planning (Type II dose
computation algorithm) and a 2.5 mm leaves MLC. Two
half arcs with different collimation angles were used to
avoid interplay effect. The dose was prescribed to 80%
isodose encompassing the PTV (48 Gy isodose around
the PTV), with an aimed dose inhomogeneity allowing a
100% maximum dose in the GTV, corresponding to a
25% over dosage located in the GTV. This method was
copied from the RTOG protocols. The later release of
the ICRU report 91 confirmed these evolutions [17]. Be-
ginning from 2010, fractions were allowed once a day
with a 48 h break in the middle of the week, but most
patients were treated with two to three fractions a week
for logistic reasons.
Setup and delivery procedures
Initially, verification of patient setup and tumor position
was performed daily using orthogonal Mega Voltage
(MV) portal images with online correction and
additional 2D-real time cine-acquisition images. On
these images, the tumor and its motion could be seen in
the Beam Eye View of some beam angles for most pa-
tients. Patients in this period treated on theTomotherapy machine were positioned with on-line
volumetric MV CT imaging before and during the frac-
tion. Systematic volumetric Cone-Beam Computed
Tomography (CBCT) came into the scene in 2010. It
was performed before the start of the session and with a
second CBCT in between two arcs in order to verify the
intra-fraction stability.
Toxicity
Radiation-induced toxicities were evaluated according to
the Common Terminology Criteria for Adverse Events
(CTCAE) version 4.0.
Follow-up
First clinical and radiological follow-up is usually done 3
months after the completion of radiotherapy and subse-
quently, every 6months. Clinical examination and chest
CT with complementary FDG-PET-CT in case of uncer-
tain recurrence were performed.
Local, regional and distant recurrences were censored.
Local recurrence includes a failure within or adjacent to
the PTV. Local control was defined as the absence of
local progression. The distinction from recurrence or
benign lung fibrosis has constantly been difficult. Suspi-
cious images were considered as local relapses without
central review. Histological confirmation was not a
prerequisite for classifying the lesion as recurrence.
Differentiation between benign radiographic changes
and local recurrence after SABR remains challenging
because many patients developed radiation-induced
fibrosis in the treated lung region [18, 19]. Therefore, it
is likely that some local relapses were actually radiation-
induced fibrosis. Regional recurrence was defined as a
failure in the hilum, mediastinum or supraclavicular fos-
sae while distant recurrence as a failure in other sites.
Statistical analysis
Median follow-up was assessed by the reverse
Kaplan-Meier method. OS was defined from the start
of radiotherapy to death by any cause. DFS was
assessed from the start of radiotherapy until death or
local, regional or distant relapse. OS and DFS were
computed with Kaplan-Meier method. Cumulative in-
cidence function (CIF) of local, regional, distant or
any recurrences were computed using competing risk
analysis with death as a competing event.
Exploratory subgroup analyses were performed
comparatively on OS, DFS and relapses according to 3
factors: treatment period (before 2010 versus after 2010),
previous (if any) cancer history (presence versus ab-
sence), and tumor stage (T1a versus T1b and T1a versus
T2). Cox proportional hazards regression models were
used to assess the association between OS and DFS rates
and these variables. Fine and Gray’s proportional
Table 1 Patient characteristics
Number of patients (N) 189
Male/female 66% (N = 124) / 34%(N = 65)
Age (median and range) 72 ± 9,8 (46–89 years)
T-stage T1a 59% (N = 111)
T1b 30% (N = 57)
T2 11% (N = 21)
Tumor size (median and range) 18 mm± 7,8 (6–37 mm)
Histology Unknown 58% (N = 109)
Known ADK 21% (N = 39)
SCC 15% (N = 29)
NOS 6% (N = 12)
Right Lung 54% (N = 102)
Upper lobe 32% (N = 61)
Middle lobe 5% (N = 9)
Inferior lobe 17% (N = 32)
Left lung 46% (N = 87)
Upper lobe 29% (N = 55)
Inferior lobe 17% (N = 32)
Abbreviations: ADK adenocarcinoma, SCC squamous cell carcinoma, NOS not
otherwise specified
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portional cause-specific hazards models were used to
estimate the subdistribution hazard ratios (sHR) and the
cause-specific hazard ratios (csHR) respectively.
The R software version 3.3.2 (The R Foundation for
Statistical Computing, Vienna, 2016) was used for statis-
tical analyses with the following packages: ggplot2,
survival and survminer.
Results
Patient characteristics
One hundred and eighty-nine patients treated with
SABR for a single primary lung lesion and also treated
with a 12 Gy × 4 fractions scheme were analyzed in this
retrospective analysis.
The median age was 72 ± 9,8 (range: 46–89 years),
66% were men, 93% were smokers or ex-smokers.
Diagnosis was histologically confirmed in 42% of the
patients (N = 80), including 21% (N = 39) lung adeno-
carcinoma, 15% (N = 29) lung squamous cell carcin-
oma and 6% (N = 12) not otherwise specified NSCLC.
The remaining 109 patients were treated without
histological confirmation (58%) due to a contraindica-
tion for a transthoracic biopsy (e.g. severe COPD
status in most of the cases).
The median tumor diameter was 18mm ± 7,8 (range
6–37 mm). Tumors were located in the right lung in
54% of the patients (N = 102), including 32% (N = 61) in
the upper lobe, 5% (N = 9) in the middle lobe and 17%
(N = 32) in the inferior lobe. Tumors were located in the
left lung in the upper and lower lobes in 29% (N = 55)
and 17% (N = 32) of the patients, respectively.
AJCC 7 TNM stage distribution was; T1a: 59%
(N = 111), T1b: 30% (N = 57), T2: 11% (N = 21); all
patients were N0 and M0.
There were 411 listed contraindications for 189
patients. The most important contraindications to sur-
gery were pulmonary (N = 137 and 72%) and/or cardiac
disfunctions (N = 80 and 42%). Only 15 patients (8%) re-
fused surgery.
Treatment and patient’s characteristics are shown in
Table 1.
Overall analysis
The median follow-up of surviving patients is 18 months
+/− 21 (interquartile range: 9–33months).
Survival
After 1, 2 and 4 years, the OS rates [95% confidence
interval] were 83% [78–89%] (N = 128), 65% [57–73%]
(N = 78) and 37% [29–47%] (N = 53), respectively. The
median survival time was 37months. DFS rates were
75% [95% CI: 68–81%] (N = 114), 49% [95% CI: 42–58%](N = 60) and 31% [95% CI: 24–41%] (N = 41) after 1,2
and 4 years, respectively (Fig. 1a and b).
Failure patterns
Overall, we observed 27 patients with local relapses
(14%), 18 with regional relapses (10%), 29 with distant
relapses (15%) and 51 with at least one relapse (27%).
At 1, 2 and 4 years, the cumulative incidence function
(CIF) of local relapses were 8% [4–13%], 15% [10–21%]
and 18% [12–25%], the CIF of regional relapses were 4%
[2–8%], 10% [6–16%] and 12% [8–19%], the CIF of
distant relapses were 9% [5–14%], 15% [11–22%] and
20% [15–28%] and the CIF of any relapses were 14%
[10–20%], 28% [22–36%], 34% [27–43%], respectively
(Fig. 2).
One patient was reclassified as locally controlled after
a salvage surgery that demonstrated the absence of
residual disease.
Subgroup analysis
Stage T1b (vs T1a) was associated with a worse OS
(univariate HR (uHR): 1.49, multivariate HR (mHR):
1.66, 95% confidence interval (CI): [1.06–2.59], p =
0.026) and a worse DFS (uHR: 1.43, mHR: 1.57, 95%CI:
[1.02–2.41], p = 0.038). Treatment period and previous
cancer history were not found to be significantly associ-
ated with OS nor DFS.
Treatment period was associated with a decrease of in-
cidence of any recurrences (univariate sHR (usHR): 0.42,
Fig. 1 a Overall survival (OS) b Disease-free survival (DFS)
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The association between treatment period and local
relapses was slight but inconclusive (usHR: 0.43, msHR:
0.47 [0.21–1.06], p = 0.07).
Previous cancer history was associated with an in-
crease of distant relapses (usHR: 3.28, msHR: 3.33
[1.34–8.27], p = 0.01). Stage T1b was not associated with
incidence of local, regional or distant relapses.
Toxicity
For all patients, grade 1 to 3 toxicities were: fatigue
(41%; N = 77), chest wall pain (10%; N = 19), dyspnea
(7%; N = 14), radiation pneumonitis (4%; N = 8, including
2% of grade 3), dermatitis (4%; N = 7), cough (3%; N = 6),rib fractures (2%; N = 3), and esophagitis (1%; N = 1). No
grade 4 or 5 toxicity was observed.
Discussion
This cohort of 189 frail patients covers a decade of
early-stage NSCLC patients treated with SABR in a sin-
gle radiation oncology department with a median
follow-up of 18 months. The 2 and 4-year OS and DFS
rates reached 65 and 37%, respectively and 49 and 31%,
respectively. At 2 and 4 years, the cumulative incidence
function (CIF) of local relapses, regional relapses and
distant relapses were 15 and 18%, 10 and 12%, 15 and
20%, respectively. The CIF of any relapses at 2 and 4
years were 28 and 34%, respectively. Our results in terms
of clinical outcomes are comparatively similar to re-
cently published data. In a recent review of 72 SABR
studies, Chi et al. reported a 5-year OS rate of 41.3%
after SABR [11].
Regarding toxicities, our data are also coherent with
the recent review of Chi et al. with a low incidence of
grade 3 radiation pneumonitis and the overall incidence
of rib fractures. The incidence of grade 3 radiation pneu-
monitis was 2% compared to 3.4% in Chi et al. and the
incidence of rib fractures for our study against Chi et al.
was 2% vs. 3.2%.
The main limitation of our study is its retrospective
nature, although all the patients are treated at a single
radiation center after referrals from several hospitals.
A second limitation is the absence of a central review
of follow-up imaging. However, most follow-up images
were reviewed in the local multidisciplinary thoracic
oncology board of the patient’s hospital, including a radi-
ologist and/or a nuclear physician. All suspected lesions
were counted as local relapses, which can be seen as an-
other limitation with an under-estimated local control.
Histological confirmation was not a prerequisite for
classifying lesions as recurrence. Differentiation between
benign radiographic changes and local recurrence after
SABR remains a challenge as many patients developed
radiation-induced fibrosis in the treated lung region [18,
19]. Therefore, it is likely that some local relapses were
actually radiation-induced fibrosis.
Patients treated without histological confirmation had
to meet the following criteria: an increase in tumor size
over time, a high FDG-PET uptake and morphological
abnormalities suggestive of malignancy. When all these
criteria are fulfilled and there were no signs of infec-
tion, the probability of benign diagnosis is less than
4% [14, 15]. The recent American Society for Radi-
ation Oncology (ASTRO) guideline acknowledges the
concept of treating with SABR without histology in
this context [20]. A high proportion of patients in
our series were treated without histological confirm-
ation (58%). This may indicate a high proportion of
Fig. 2 Cumulative incidence function (CIF) of local, regional, distant or any relapses. CIF of relapses and death are represented in black and grey
respectively. CIF are presented for the whole group (All), in two groups following the period (before 2010 and after 2010), the existence of a
previous cancer history (PCH) and tumor stage (T1a versus T1b, stage T2 is not shown)
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tion for a transthoracic biopsy.
As compared to the recent international Advisory
Committee on Radiation Oncology Practice (ACROP)
recommendations, our methods especially since 2010,
are in tandem in terms of the radiation preparation, pre-
scription methods, delivery, and technologies [21]. One
difference with our group of patients is the recommen-
dation of more frequent use of post-therapeutic biopsies
if a relapse is suspected for patients eligible for salvage
treatments. This was not the current practice in our
patient series, as 58% were already considered ineligible
for a transthoracic biopsy during the initial diagnosis.
Another major difference with these recommendations
is the radiation dose. Our 12 Gy × 4 fractions schema
corresponds to a BED with an alpha/beta of 10 in the
linear quadratic model (BED 10) of 106 Gy, superior to
the favorable 100 Gy threshold. The ACROP consensus
proposed to keep the 12 Gy × 4 fractions schema for
tumors with a substantial contact with the chest wall, or
an adapted 15 Gy × 3 fractions escalated schema (BED
113 Gy), and for the best prognosis patients, a much
higher dose of 18 Gy × 3 fractions. Considering our
slightly lower than expected local control (74% for the
whole patient cohort at the median follow-up of 4 yearsand 1 year), our prescriptions nowadays are sometimes
adapted in accordance to ACROP recommendation (18
Gy × 3 fractions) depending on the clinical situation and
when a higher dose can safely be delivered.
The substantial technological advancements during
the recruitment of patients can be viewed as another
methodological weakness, although they represent real-
life practice. The patients were treated with a nominally
constant dose prescription. However, considering the
fact that the dose was first prescribed at the isocenter
using a pencil beam algorithm, and later at the isodose
encompassing the PTV using an AAA algorithm, proved
a significant dose escalation by at least 25%. The studied
outcome parameters were not clearly improved by the
new technologies or with the derived prescription
method, but we remark a slight association between the
treatment period and the incidence of any recurrences.
However, the decrease in relapses is concomitant with
an increase of deaths. The positive impact of the treat-
ment period must therefore be further demonstrated.
The limitations of this non-randomized comparison
highlights the difficulties in radiation oncology to assess
the potential clinical improvement of new technologies,
as illustrated by Chi et al. when trying to compare SABR
with hypo-fractionated particle beam therapy [11].
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apy machine and methods (dose computation, arc
delivery, volumetric image guidance methods, full
breathing cycle gating) were performed in 2010, while
the improved clinical outcome (improved local control)
was only hypothesized in our 2017 review and is not
even confirmed.
Conclusion
We observed a long-term local control and survival after
SABR for peripheral stage I NSCLC in this large series
of patients with the expected low toxicity.
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